Profusa, Inc.

NVAC, the blank-check company associated with Profusa, Inc., filed an 8-K with the Securities and Exchange Commission on February 2, 2026, disclosing a material event in its ongoing transaction process. Profusa is a digital health and medical device company specializing in implantable biosensor technology engineered for continuous, real-time monitoring of human physiology, positioning the proposed combination squarely within the healthcare technology sector. The current status of the deal reflects an active post-IPO phase, with the filing assigned accession number 0001213900-26-010808 marking a notable point in the SPAC's lifecycle. To access complete filing histories, sponsor profiles, and deal timelines for NVAC and the full SPAC universe, sign up for full data on SpacDesk.